RxDoctor Payments Data

Felipe Suplicy

Psychiatry · Rome, GANPI 1134338908

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $658 of the $848 with a category attached, or 77.7%. Alnylam Pharmaceuticals Inc. accounts for 91.5% of it on its own, with 2 other manufacturers making up the rest.

$848in general payments, 2019–2025

Across 6 payments — averaging $141.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$775
  • AbbVie$49
  • Otsuka America Pharmaceutical, Inc.$23
$2,297,483in research payments, 2019–2025

Across 409 payments — averaging $5617.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Axsome Therapeutics, Inc.$585K
  • AbbVie$525K
  • Modernatx, Inc.$418K
  • H. Lundbeck A S$277K
  • Janssen Research & Development, LLC$230K
  • Ipsen Innovation$121K
  • plus $142K from 6 others

What the payments were for

  • Travel & lodging$65878%
  • Food & beverage$18922%

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$848 in reported general payments places this provider in the 65th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Other psychiatry in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →